Similar companies
| Company | Transaction Value | |
|---|---|---|
 |
OcugenOCGN |
$78,000 |
 |
AmarinAMRN |
$410,000 |
 |
Gilead SciencesGILD |
-$1.06B |
 |
Anavex Life SciencesAVXL |
-$6.3M |
 |
AmgenAMGN |
-$98M |
Insider Transactions
| Name | Transaction Date | Sold / Bought | Shares | Price | Value |
|---|---|---|---|---|---|
| MESSEMER DEBORAH M. | Jun 10, 2025 | Sell | 36,885 | $1.42 | $52,000 |
| Yoshiyama Annie | Apr 21, 2025 | Sell | 9,601 | $1.41 | $14,000 |
| Chang David D | Mar 14, 2025 | Sell | 46,668 | $1.96 | $91,000 |
| Beneski Benjamin Machinas | Mar 14, 2025 | Sell | 5,488 | $1.975 | $11,000 |
| MESSEMER DEBORAH M. | Feb 18, 2025 | Sell | 13,313 | $2.43 | $32,000 |
| MOORE TIMOTHY L. | Feb 3, 2025 | Sell | 14,746 | $1.71 | $25,000 |
| Chang David D | Feb 3, 2025 | Sell | 46,003 | $1.68 | $77,000 |
| Roberts Zachary | Feb 3, 2025 | Sell | 18,832 | $1.7 | $32,000 |
| Douglas Earl Martin | Feb 3, 2025 | Sell | 6,404 | $1.71 | $11,000 |
| Parker Geoffrey M. | Feb 3, 2025 | Sell | 4,361 | $1.73 | $7,500 |
| Roberts Zachary | Jan 21, 2025 | Sell | 27,199 | $1.78 | $48,000 |
| MESSEMER DEBORAH M. | Dec 9, 2024 | Sell | 9,136 | $2.18 | $20,000 |
| Humer Franz B | Dec 5, 2024 | Sell | 9,221 | $2.16 | $20,000 |
| MESSEMER DEBORAH M. | Jun 18, 2024 | Sell | 18,641 | $2.2793 | $42,000 |
| Humer Franz B | May 30, 2024 | Sell | 11,200 | $2.3376 | $26,000 |
| Belldegrun Arie | May 16, 2024 | Buy | 1,724,137 | $2.9 | $5M |
| Parker Geoffrey M. | Jan 30, 2024 | Buy | 190 | $3.595 | $680 |
| MESSEMER DEBORAH M. | Dec 18, 2023 | Sell | 18,640 | $2.6994 | $50,000 |
What's the latest insider transaction for Allogene Therapeutics?
The most recent insider transaction for Allogene Therapeutics was conducted by MESSEMER DEBORAH M., who sold 36,885 shares on June 10, 2025 at a price of $1.42 per share.
Which insider bought the most ALLO stock over the last two years?
Belldegrun Arie has bought the most ALLO stock in the last 2 years, with a total value of $5M.
Which insider has sold the most ALLO stock over the last two years?
MESSEMER DEBORAH M. has sold the most ALLO stock in the last 2 years, with a total value of $200,000.
What is the total value of insider transactions for Allogene Therapeutics (ALLO) in the last 2 years?
According to our estimates, the total value of insider transactions for Allogene Therapeutics in the last 2 years is positive, amounting to $4.4M. This indicates that insiders have predominantly bought shares, showcasing their confidence in the company's future prospects.
How do insider transactions over the last 2 years reflect on Allogene Therapeutics' market confidence?
Over the last 2 years, insider transactions for Allogene Therapeutics have largely consisted of selling shares, which could suggest various personal or financial motivations among insiders. The higher number of sales might require investors to investigate further, considering insiders might have insights or reasons not immediately apparent to the public.
Why is monitoring insider trading activity important for investors?
Monitoring insider trading activity is important because it provides insights into the confidence levels of a company's insiders, such as executives and directors, regarding the company's future prospects. Insider buying can signal optimism, suggesting the stock may be undervalued, while insider selling might raise questions about the stock's upcoming performance. However, it's essential to consider that sales can also occur for personal financial reasons. Insider trading activity is a valuable indicator that, when combined with other data, can help inform investment decisions.
